EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.95) by 14.74 percent. This is a 28.24 percent decrease over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $507.000 thousand which beat the analyst consensus estimate of $406.857 thousand by 24.61 percent. This is a 90.49 percent decrease over sales of $5.333 million the same period last year.